Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...
Updated guidelines on allogeneic hematopoietic stem cell transplantation for myelofibrosis examine spleen-related ...
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on KROS stock, giving a Buy rating yesterday. Thomas Smith’s ...
At this time, I would like to welcome everyone to Karyopharm Therapeutics third quarter 2024 financial results conference ...
The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...
Medpage Today on MSN10d
Asymptomatic or Minimally Symptomatic MyelofibrosisAbout 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...
Karyopharm (KPTI) announced that, following feedback from the FDA, the company will be replacing Total Symptom Score Improvement of greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback